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23. ADouble Blind Study of Phenprocoumon Prophylaxis
Af ter Myocardial Inf arction
A. F{rNsrN, F. Knors, L. M. veN Dvcr<, N. Frrrns, H. C. Hnuxnn and
E. A.'LoErrcsn'r
There is a growing opposition against life-long anticoagulant reatment. In the
beginning of 1.964 we therefore decided to perform a double blind study with
patients already treated with phenprocoumon and cared by our Thrombosis
Service for more than one year af.ter a prorren myocardial infarction. No males
younger than 45 or older than 75 years and no females were included in the
study, their number being too small for separate statistical evaluation. Immo-
bilized patients and patients with atrial fibrillation or a known malignant
disease were excluded as well. The remnant was an almost unselected group of
about 250 male out-patients aged 45 to 75 years, and having been under
control for a period of 1 to 1.0 years. They all had proven willingness and
suitabilicy for anticoagulant treatment. This group was divided into three age-
classes and the patients of each class were ranged according to the date of
admissio,n to the Thrornbosis Service. \fe decided by lot that patients with odd
numbers had to continue treatment with phenprocoumon, while those with even
numbers received placebo tablets.
Table 1 shows the data concerning the patients entering the trial. Both groups
are closely similar as to age and lenght of the pre-trial anticoagulant period and
fairly comparable as to other relevant criteria, Both phenprocoumon and placebo
tablets were put at the disposal of the patients by the Thrombosis Service'r''r. As
for the rest, the therapeutic and control regimen was the same in both groups.
The attending physician knew the kind of trial we performed, but not the group
to whidr his patient belonged. In case of reinfarction, cardiovascular deteriorat-
ion, bleeding etc. the attending physician contacted one of us, who was unknown
with the particular type of treatment of the patient; the decision as to the
'r From the Haematology Section of the Department of Internal Medicine (Head: Prof. J.
Mulder, M.D.), the Department of Cardiology (Head: Prof. H. A. Snellen, M.D.), University
Hospital, Leyden, and the Thrombosis Service, Leyden (Head: E. A. Loeliger, M.D.), The
Netherlands.
't;t The authors wish to thank the'firm F. Hoffmann-La Rodre for kindly furnishing both the
phenprocoumon (marcoumar) and the placebo tablets.
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Table 1. Pertinent data concerning the ?atients enteri'ng the trial.
Phenprocoumon Placebo
45- 55- 65-7! total 45- 55- 65-7, total
Number of patients
Mean age
Mean'pre-trial' anticoagulant
period (in months)
Diabetes mellitus
Hypertension
(syst. ) 180, diast. > 100)
Re-infarction during'pre-trial'
anticoagulant period
};;i:::*las 
indication for long-
J +
50.5
35.4
2
)
7
3
57
59.4
37.0
1
8
n
6
37
67.5
46.8
i
128
59.4
39.4
4
t 5
1
I J
3 l
39.2
0
1
I
n
60
59.4
39.3
I
7
z
5
J I
69.1
44.7
2
7
1,22
59.6
40.6
1
1 0
3
6
prospectiye fteatment of the patient was made before the kind of treatment was
known. In case of a new indication for anticoagulant therapy or a contra-indi-
cation the patient was remoyed from the trial.
Concerning the intensity of treatment: our aim was thrombotest percentage
between 5 andlOolo, in cases with a contra-indication, however (such as age over
65, hypertension, cerebrovascular accident, history of peptic ulcer), 7-l3olo.
Actually, under these two premises, the overall mean thrombotest activities were
7.5o/o, and 8.2olo (standard deviation 1,.48010), respectively (standard deviations
of the individual means 1,.25o/0, and 1.480/.0, resp.).
rabte 2' ctassificatian ot,:ltil:::irri:'J,:il";;#:x;:on,nlf';y:,,tradted' witb phenpro-
Thrombotest o l o
( 5olo
5-100/o
) 10-150/o
) l5-2dlo
) 20-25olo
) 25-3@lo
) 3d/o
6 .8
68.2
79.1.
A N
1.2
A A
U . J
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Table 2 illustrates intensity and stability of the hypocoagulability achieved;
on\y about 6o/o of 'lhrombotest, ya\ues'were higher than 150/u.
Results obtained until the middle of august 'J.965 are summarized in Table 3.
The placebo-treated group did far worse than the coumarin-treated group. The
difference in re-infarction rate was; 1.2 per 100 man years of exposure in the
phenprocoumon against 8.7 in the placebo-group. The difference is statistically
highly significant. The difference in mortality, being 4.2 per 100 man years
exposure in the phenprocoumon-group and7,2 per 100 man years of exposure
in the placebo-group, is not significant.
Table 3. Synopsi.s ot' the reswks obtained.
Placebo
Number of patients
April 1964
August 1965
Months of treatment
'Sudden' death
Re-infarction
Important cardiac deterioration
Dysbasia intermittens
Cerebrovascular accident
Venous thrombosis
Total cardiovascular complications
Severe bleeding complication
Number of drop-outs
128
112
2ot6.ss
7
2
1
I
122
8 1
t657.08
8
12 (r died)
7 (1 died)
2 (1 died)
2
34
1**
7
t1,
{'subarachnoidal bleeding with complete recovery, also rubricated under drop-uts.
::-'r' lethal intracerebral haemorrhage, akerdy rubricated under cerebrovascular accident.
Furthermore, all important is the observation that there was no correlation
between incidence of death, re-infarction as well as other cardio-vascular com-
plication and length of pre-treatment period. Also we did not observe a rebound
phenomenon in the group of patients in which the phenprocoumon tablets were
changed into placebo tablets.
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Finally, the question arises as to whether the number of bleeding complications
has been detrimental to the results obtained. Relevant data are given in Table 4.
The patient who died from a cerebral bleeding belonged to the placebo group.
Table 4. Bleeding complications classifed accord.ing to tlte severity, i.e. therapewtic measures.
Placebo
No change in dosage
Temporary lowering of dosage
Administration of vitamin Kt
Blood transfusion
't lethal intracerebral bleeding, '"'r two macrohaematurias, one subaradrnoidal bleeding.
In conclusion
Our study clearly demonstrates the benefit that can be expected from intensive
long-term anticoagulant treatment after myocardial infarction. The negative or
less impressive results reported in limerature most probably originate in the less
intensive treatment given. For instance, in one of the most recent reports with
negative results, half of the time the P and P value was more than 25olo, which
corresponds to more than l5olo thrombotest, while in our trial this happened in
only about 60lo of the time. The stability and intensity of hypocoagulability
instituted in our patients, we could only achieve under the following conditions:
1. the use of a long-acting coumarin drug such as phenprocoumon fMarcoumar];
2. a thrombosis service, where experienced nurses, besides taking blood and
performing the coagulation check, take an active part in all other aspects of
anticoagulant treatment;
3. close cooperation of the staff of the thrombosis service with the attending
physicians.
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Addendum
A detailed report of the results will be published elsewhere.
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